Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Rogaine Foam ANDA May Help Extend Record Growth

This article was originally published in The Tan Sheet

Executive Summary

Perrigo's regulatory green light to market the first OTC generic of Men's Rogaine Foam further extends the pipeline that has kept the firm on a streak of record earnings.

You may also be interested in...



In Brief

Perrigo debuts Rogaine Foam equivalent; Pfizer patent suit applies heat to J&J/McNeil; Merck KGaA consumer unit beats forecast; Abbott seeks expanded vitamin D3 use; Hi-Tech Pharmacal adds to homeopathics portfolio; more news In Brief.

Perrigo To Launch Private Label Mucinex, Prevacid, With An Eye On Lipitor

Private label giant Perrigo is readying generic competitors to Reckitt Benckiser’s Mucinex and Takeda Pharmaceuticals’ Prevacid, CEO Joseph Papa says.

Perrigo To Launch Private Label Mucinex, Prevacid, With An Eye On Lipitor

Private label giant Perrigo is readying generic competitors to Reckitt Benckiser’s Mucinex and Takeda Pharmaceuticals’ Prevacid, CEO Joseph Papa says.

Related Content

Topics

UsernamePublicRestriction

Register

PS105037

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel